CASP8 and early-onset autosomal dominant Alzheimer disease: Currently, therapeutic agents targeting CASP8 include bardoxolone, under investigation for lymphoma and solid tumor management; bryostatin 1, explored for HIV infection and Alzheimer’s disease intervention; AN-9, scrutinized for liver cancer, lung cancer, melanoma, and leukemia; trichostatin A; oleandrin, assessed for lung cancer therapy and chemotherapy-induced adverse effects.